CONTINGENT CONSIDERATION (GAINS) CHARGES, RESTRUCTURING CHARGES AND OTHER - Narrative (Details) - USD ($) |
1 Months Ended | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|---|
Feb. 29, 2024 |
Sep. 30, 2024 |
Sep. 30, 2023 |
Sep. 30, 2024 |
Sep. 30, 2023 |
|
Business Acquisition [Line Items] | |||||
Changes in contingent consideration | $ (5,541,000) | $ (3,847,000) | |||
Charges incurred | $ 1,193,000 | $ 173,000 | 7,724,000 | 1,109,000 | |
Acquisition-related expenses | 285,000 | 390,000 | 689,000 | 1,588,000 | |
EXPAREL | |||||
Business Acquisition [Line Items] | |||||
EXPAREL at average sales price margin | 6.00% | ||||
iovera° | |||||
Business Acquisition [Line Items] | |||||
Additional Medicare reimbursement per patient (up to) | $ 255.85 | ||||
Flexion | |||||
Business Acquisition [Line Items] | |||||
Changes in contingent consideration | (3,244,000) | 2,793,000 | (5,541,000) | (3,847,000) | |
Acquisition-related expenses | $ 300,000 | $ 400,000 | $ 700,000 | $ 1,600,000 |